Sagimet Biosciences (SGMT) Advances with Denifanstat as Q3 Earnings and Upcoming Catalysts Take Center Stage

Sagimet Biosciences (Nasdaq: SGMT) announced its third‑quarter financial results for the period ended September 30, 2025, alongside major clinical‑stage updates that may drive its next phase of growth. On the financial front, the company reported a net loss of $12.9 million for Q3 and $41.5 million for the first nine months of 2025. Key expense categories include R&D spending of $9.7 million for Q3 and $32.3 million for nine‑month period, and G&A costs of $4.6 million in Q3 and $13.8 million for nine months. As of September 30, 2025, Sagimet held $125.5 million in cash and marketable securities—providing a runway for ongoing programs. On the clinical front, the headline is its lead fatty acid synthase (FASN) inhibitor, Denifanstat. The company disclosed that in September 2025 it began dosing in a Phase 1 open‑label pharmacokinetic (PK) study combining denifanstat with Resmetirom, a thyroid hormone receptor‑beta (THR‑β) agonist. ~40 healthy adult participants have been enrolled across two cohorts to evaluate single and multiple‑dose PK, drug‑drug interaction potential, and safety. Topline readout from this combination trial is targeted in 1H 2026, and if positive, may allow progression into proof‑of‑concept studies in patients with metabolic dysfunction‑associated steatohepatitis (MASH) and advanced fibrosis (F4). Meanwhile, through its China partner Ascletis Bioscience, Sagimet is advancing an NDA submission for denifanstat in moderate‑to‑severe acne vulgaris. Ascletis completed a pre‑NDA consultation with China’s National Medical Products Administration (NMPA) and plans to file following a 480‑patient Phase 3 trial that reportedly met all efficacy endpoints. Additionally, Sagimet has initiated a first‑in‑human Phase 1 trial of its second FASN inhibitor, TVB‑3567, to explore an acne indication. In summary, Sagimet is positioning itself with a dual‑track clinical strategy: advancing denifanstat in liver‑metabolism/fibrosis (“MASH”) through the combination trial, while pursuing dermatology (acne) via its partner in China and its own second program. With a solid cash cushion and multiple upcoming catalysts (combination trial readout, partner NDA filing), the company appears well‑positioned—but as always, execution risk and regulatory outcome uncertainty remain. && #Sagimet #Denifanstat #BiotechEarnings #FASNInhibitor && #Sagimet #Denifanstat #BiotechEarnings #FASNInhibitor #SlimScan #GrowthStocks #CANSLIM